Naslov
STROMAL IL-6 AS A DISEASE PROGRESSION MARKER FOR HEADAND NECK SQUAMOUS CELL CARCINOMA

Autori
Tomasovic Loncaric, C ; Fucic, A, Bisof, V ; Rakusic, Z ; Andabak, M ; Vucicevic Boras, V

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Lib Oncol. 2018 ; 46(Suppl 1): 89-89 / - , 2018, 89-89

Skup
HDIR-5: Translating Science to Medicine - Targets and Therapeutics" - Fifth Meeting of the Croatian Association for Cancer Research with International Participation

Mjesto i datum
Zagreb, Hrvatska, 08.11.2018. - 10.11.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
IL-6, HNSCC

Sažetak
Patients suff ering from head and neck squamous cell cancer (HNSCC) still have low survival rate due to late diagnosis, insuffi cient knowledge on chemo- and radioresistance and lack of reliable prognostic and predictive biomarkers. As IL-6 defi nes the tumorigenic capacity and motility of cancer stem cells there is raised interest for its inclusion as a marker of cancer aggressiveness and concomitant decision upon therapy. The aim of this study was to investigate stromal and epithelial IL-6 levels in HNSCC. Analysis of IL-6 in 51 HNSCC (24-non-metastatic and 26 metastatic cancers) patients who underwent radical surgery was performed by immunohistochemistry in the tumour epithelium and in the tumour stroma. Mean age of patients was 63±12 years. IL-6 values in the epithelium and stroma positively correlated (Spearman’s rho 0.69, p- value < 0.001). IL-6 was higher in patients with metastases than in non-metastatic patients, and this diff erence was more pronounced in the stroma (median 18.00 with interquartile range [10.00, 57.50], compared to 8.00 [1.00, 18.50] in patients without metastases) than in the epithelium (20.00 [10.00, 37.50] versus 11.50 [5.00, 30.00]). Our results suggest that (a) stromal IL-6 might be the marker of neoplastic progression, (b) need for both stromal and epithelial IL-6 analysis in patients with HNSCC. Stromal production of IL-6 may contribute in the future profi ling of tumor aggressiveness, poor response to the chemoradiotherapy and regarding decision on immunotherapy.

Izvorni jezik
Engleski

POVEZANOST RADA